CClinicalTrials.gg
RecruitingNCT06030479Updated Sep 11, 2023

Topical Adrenaline Versus Warm Saline Solution for Minimizing Intraperitoneal Bleeding During Caesarian Delivery for Placenta Previa / Accreta Spectrum ( PAS)

An interventional study of Topical adrenaline and Warm saline in Placenta Accreta and Placenta Previa, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-11.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

Placenta accreta spectrum (PAS), encompassing the terms placenta accreta, increta, and percreta; abnormally invasive placenta; morbidly adherent placenta; and invasive placentation, is a leading cause of life-threatening obstetric haemorrage . Currently, more than 90% of women diagnosed with PAS also have a placenta praevia , and the combination of both conditions leads to high maternal morbidity and mortality due to massive haemorrhage at the time of birth . Maternal mortality of placenta praevia with percreta has been reported to be as high as 7% of cases .

Adrenaline has also been demonstrated to be a reasonable hemostatic agent because of its low cost, low risk, powerful vasoconstrictor, and platelet aggregation. Topical use of adrenaline is an effective and reasonable hemostatic agent in tonsillectomy.

Read the detailed description
  • Population of study: A total of 84 pregnant patients with placenta previa / Accreta spectrum.
  • Study location: Obstetrics and Gynecology Kasr Al-Ainy Hospital , Faculty of Medicine , Cairo University.

This is a randomized controlled trial including a total number of 84 patients representing study group , randomized in 2 equal groups , using computer generated randomization sheet on (Medcalc ®) .

Group A : Topical adrenaline group (n=42)

Group B : Warm saline Group (control) (n=42)

The aim of the study is to evaluate the efficacy of topical adrenaline for decreasing intraperitoneal bleeding during caesarian section for placenta previa/ Accreta spectrum (PAS).

02

Conditions studied

  • Placenta Accreta
  • Placenta Previa
03

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age from 18 to 40 years.
  • BMI \< 35.
  • Pregnant patients with placenta previa .
  • Placenta accrete spectrum.
  • Vitally stable .

Exclusion criteria

Exclusion Criteria:

  • Vitally unstable .
  • Massive pre- or intra-operative bleeding.
  • Medical disorders ( e.g. : hypertension , cardiac .... )
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    Topical Adrenaline Group

    Topical adrenaline group

    Drug: Topical adrenaline

  • Placebo comparator
    Warm saline Group

    Warm saline Group

    Drug: Warm saline

Interventions

  • DrugTopical adrenaline

    Skin is incised midline sub-umbilical incision , bladder dissection will be done , uterus will be incised by vertical upper segment incision , followed by delivery of the baby. Surgical assessment and decision for either conservative management or CS hysterectomy will be done. After completion of surgical procedure , surgical field is observed for major bleeding and patients are subjected to intervention Packing the pelvic surgical field with towels fully saturated with adrenaline 1:10000 solution.

  • DrugWarm saline

    Skin is incised midline sub-umbilical incision , bladder dissection will be done , uterus will be incised by vertical upper segment incision , followed by delivery of the baby. Surgical assessment and decision for either conservative management or CS hysterectomy will be done. After completion of surgical procedure , surgical field is observed for major bleeding and patients are subjected to intervention Packing the surgical field with towels fully saturated with warm saline solution ( 50 degrees).

05

What researchers measure

Primary outcomes

  1. control of intra-operative bleeding from surgical field.

    control of intra-operative bleeding from surgical field if bleeding stopped , or minimal oozing , towel are not soaked with blood and improvement of general condition with no hemoglobin drop.

    Time frame: 30 minutes after application of topical drug

Secondary outcomes

  1. Need for hemostatic sutures , uterine artery ligation , internal iliac artery ligation , hysterectomy

    Need for hemostatic sutures , uterine artery ligation , internal iliac artery ligation , hysterectomy

    Time frame: if bleeding continued 30 minutes after topical drugs

  2. immediate maternal complications ( postpartum haemorrage , DIC , hysterectomy , maternal mortality , ICU admission , …)

    immediate maternal complications ( postpartum haemorrage , DIC , hysterectomy , maternal mortality , ICU admission , ...)

    Time frame: 24 hours after delivery

06

Study locations

1 of 1 sites recruiting
07

References and documents

Publications

  • Solheim KN, Esakoff TF, Little SE, Cheng YW, Sparks TN, Caughey AB. The effect of cesarean delivery rates on the future incidence of placenta previa, placenta accreta, and maternal mortality. J Matern Fetal Neonatal Med. 2011 Nov;24(11):1341-6. doi: 10.3109/14767058.2011.553695. Epub 2011 Mar 7. PubMed 21381881 ↗
  • Jauniaux E, Bhide A, Kennedy A, Woodward P, Hubinont C, Collins S; FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Prenatal diagnosis and screening. Int J Gynaecol Obstet. 2018 Mar;140(3):274-280. doi: 10.1002/ijgo.12408. No abstract available. PubMed 29405319 ↗
  • Hatton RC. Bismuth subgallate-epinephrine paste in adenotonsillectomies. Ann Pharmacother. 2000 Apr;34(4):522-5. doi: 10.1345/aph.19216. PubMed 10772440 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT06030479
Lead sponsor
Cairo University
Responsible party
Bassiony Dabian (lecturer of obstetrics and gynecology, Cairo University) — Principal investigator
First posted
Sep 11, 2023
Start date
Feb 1, 2023
Primary completion
Oct 15, 2023 (estimated)
Completion
Oct 25, 2023 (estimated)
Last update
Sep 11, 2023

Study contacts

bassiony dabian, MD
Contact
bassiony.dabian@gmail.com
1095195513

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion